Navigation Links
ULURU Inc. Raises $140,000 in Convertible Debt Offering
Date:6/14/2011

ADDISON, Texas, June 14, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced it has completed a $140,000 convertible debt financing with Kerry P. Gray, the Company's Chairman, President, and Chief Executive Officer. The Company intends to use the funds for general corporate purposes.

The convertible notes will bear interest at the rate of 10.0% per annum, with annual payments of interest commencing on July 1, 2012. The full amount of principal and any unpaid interest will be due on June 13, 2014. The outstanding principal balance of the notes may be converted into shares of ULURU Inc. common stock, at the option of the note holder and at any time, at a conversion price of $0.08 per share or 1,750,000 shares of common stock. The company may force conversion of the convertible note if the common stock trades for a defined period of time at a price greater than $0.12. The convertible note is secured by the grant of a security interest in the inventory, accounts receivables and capital equipment held by the Company. The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements.

As part of the convertible debt financing, Mr. Gray will also receive a warrant to purchase up to 525,000 shares of ULURU Inc.'s common stock. The warrant has an exercise price of $0.08 per share and is exercisable at any time until June 13, 2016.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucos
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... today announced that The New England Journal ... II data for the investigational drug iniparib* (BSI-201) ... triple negative breast cancer (mTNBC) when iniparib was ...
... 2011 MiMedx Group, Inc.  (OTC Bulletin ... and marketer of patent protected biomaterial-based products, announced today ... leader in the development of tissue processing techniques for ... amnion membranes. The deal was originally announced on December ...
Cached Medicine Technology:Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 2Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 3Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 4Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 5Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 6MiMedx Completes Acquisition of Surgical Biologics 2MiMedx Completes Acquisition of Surgical Biologics 3MiMedx Completes Acquisition of Surgical Biologics 4
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
(Date:9/19/2014)... Albany,NY (PRWEB) September 19, 2014 ... Dr. Reed Ference, is excited to announce the ... with periodontal disease, gingivitis and those needing dental ... the LANAP® laser treatment removes the fear factor ... no stitches, less discomfort and bleeding make, this ...
(Date:9/19/2014)... 2014 York University researchers say a simple ... to detect heightened risk for developing Alzheimer,s disease ... telltale behavioural signs of dementia., Faculty of Health ... who led the study asked the participants to ... on dual screen laptop computers. The test aimed ...
(Date:9/19/2014)... 2014 Recent financial data reveled ... increased their sales by 7% in the last quarter ... industry can be used as a bellwether to determine ... This data has been proven to show trends with ... transportation. Other non-trucking data is largely influenced by international ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... , Recent CBO analysis ... 3 A new actuarial analysis by Oliver Wyman, Inc. ... market will be 54 percent higher than they are today ... Protection and Affordable Care Act (PPACA), excluding the impact of ...
... a new factor that is necessary for the development ... of malignant childhood brain cancer. HHMI investigator Huda Y. ... medulloblastoma from developing in mice by shutting down production ... team,s findings, reported in the December 4, 2009, issue ...
... , NEW YORK, Dec. ... H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic ... at least 6,500 fatalities. Since there is no longer ... undoubtedly understate the real situation. , (Photo: ...
... , CHICAGO, Dec. 3 An ... called platelet-rich plasma therapy (PRP), is showing strong potential ... a prominent dental researcher and editor of the ... Rutkowski, DMD, PhD, reported at the recent annual scientific ...
... low number of new cases created by a single ... as vaccination, social distancing and the use of antiviral ... the virus, suggests an epidemiological modelling study http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091807 ... Medical Association Journal ) www.cmaj.ca . ...
... ... specializing in the emerging medical travel space, announced that international medical quality authority, Dr. ... ... 2009 –- Satori World Medical, a leading global healthcare company specializing in the emerging ...
Cached Medicine News:Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4Health News:Researchers identify gene that spurs deadly brain cancer 2Health News:Researchers identify gene that spurs deadly brain cancer 3Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: